This site will be intermittently unavailable for routine maintenance starting on Friday, July 19th at 9pm and lasting through Sunday July 21st.



Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Read More

Please enter your email. Your password will be reset and a temporary password will be sent to the email address on file.